AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the third quarter ended September 30, 2019.
“Driven by our vision of being the leading biotechnology company with a focus on human aging, in the third quarter we advanced our product development on numerous fronts,” said Michael D. West, Ph.D., founder and Chief Executive Officer. “Our recent build-out of GMP-compliant manufacturing laboratory space will facilitate our manufacture of master cell banks such as those that carry the UniverCyteTM genetic modification for off-the-shelf cell-based regenerative therapy.”
Recent Highlights
- Dr. West and AgeX were included in a feature article that was part of the cover theme in MIT Technology Review magazine. The September-October edition of this respected magazine from the Massachusetts Institute of Technology, called “The longevity issue” had the cover theme, “Old Age is Over!”
- On the company’s behalf, Dr. West participated at two industry and investor conferences during the quarter. He discussed the company’s metabolic and diabetes-related programs as part of a panel at Metabesity 2019, October 15-16 in Washington, DC. He also delivered an investor presentation at the H.C. Wainwright (Rodman & Renshaw) Investment Conference, September 8-10 in New York City.
- The company published two papers in the peer-reviewed scientific journal Regenerative Medicine, from Future Medicine. The first, “Toward a Unified Theory of Aging and Regeneration,” outlines the theory behind the company’s induced tissue regeneration (iTR) program. The second, “Engineering strategies for generating hypoimmunogenic cells with high clinical and commercial value,” is a joint paper with Juvenescence. It includes a review of the most promising approaches to producing UniverCyte™ cells and shares a previously unpublished in vivo mouse observation.
- We continue to make progress to engineer pluripotent cell lines with immune tolerance UniverCyte™ technology to generate hypoimmunogenic (universal) cells.
Second Quarter 2019 Operating Results
Revenues: Total revenues for the three months ended September 30, 2019 were $411,000, as compared with $380,000 in the same period in 2018. AgeX revenue is primarily generated from subscription and advertising revenues from the GeneCards® online database through its subsidiary LifeMap Sciences, Inc. 2019 revenues also included $41,000 of grant revenue from the NIH. AgeX had no grant revenues in the same period in 2018.
Operating expenses: Operating expenses for the three months ended September 30, 2019 were $3.6 million, as compared with $2.6 million for the same period in 2018. On an as-adjusted basis, operating expenses for the three months ended September 30, 2019 were $2.9 million as compared to $2.2 million for the same period in 2018.
The reconciliation between operating expenses determined in accordance with accounting principles generally accepted in the United States (GAAP) and operating expenses, as adjusted, a non-GAAP measure, is provided in the financial tables included at the end of this press release.
Research and development expenses for the three months ended September 30, 2019 were $1.4 million, as compared with $1.3 million in the same period in 2018.
General and administrative expenses for the three months ended September 30, 2019 were $2.2 million, as compared with $1.3 million in the same period in 2018.
Net loss attributable to AgeX: The net loss attributable to AgeX for the three months ended September 30, 2019 was $3.2 million, or ($0.09) per share (basic and diluted) compared to $2.2 million, or ($0.06) per share (basic and diluted), for the same period in 2018.
Balance Sheet Highlights
Cash, and cash equivalents, including restricted cash totaled $3.8 million as of September 30, 2019, in addition to which we have $1.5 million remaining available for borrowing under a credit facility provided by Juvenescence Limited, which brought our total available capital to $5.3 million. However, under accounting standard ASC 205-40 Presentation of Financial Statements-Going Concern, AgeX’s cash and cash equivalents of $3.8 million as of September 30, 2019 and the loan facility by Juvenescence may not be sufficient, without raising additional capital and reducing expenditures, to satisfy AgeX’s anticipated operating and other funding requirements for the next twelve months from the issuance of its interim condensed consolidated interim financial statements.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem® and UniverCyte™ manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem® is AgeX’s delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.
For more information, please visit www.agexinc.com or connect with the company on Twitter, Facebook, and YouTube.
Forward-Looking Statements
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of AgeX’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
AGEX THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS, EXCEPT PAR VALUE AMOUNTS) | ||||||||
September 30, 2019 | December 31, 2018 | |||||||
(Unaudited) | ||||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash and cash equivalents | $ | 3,768 | $ | 6,707 | ||||
Accounts and grants receivable, net | 234 | 131 | ||||||
Prepaid expenses and other current assets | 688 | 1,015 | ||||||
Total current assets | 4,690 | 7,853 | ||||||
Property and equipment, net | 1,010 | 90 | ||||||
Deposits and other long-term assets | 193 | 19 | ||||||
Intangible assets, net | 2,290 | 2,709 | ||||||
TOTAL ASSETS | $ | 8,183 | $ | 10,671 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
CURRENT LIABILITIES | ||||||||
Accounts payable and accrued liabilities | $ | 1,757 | $ | 1,366 | ||||
Related party payables, net | 319 | 132 | ||||||
Deferred revenues | 219 | 317 | ||||||
Right-of-use lease liability, current portion | 417 | - | ||||||
Insurance premium liability and other current liabilities | 195 | 625 | ||||||
Total current liabilities | 2,907 | 2,440 | ||||||
Loan due to Juvenescence, net of debt issuance cost | 191 | - | ||||||
Right-of-use lease liability, net of current portion and other noncurrent liabilities | 142 | - | ||||||
TOTAL LIABILITIES | $ | 3,240 | $ | 2,440 | ||||
Commitments and contingencies | ||||||||
STOCKHOLDERS’ EQUITY | ||||||||
Preferred stock, $0.0001 par value, authorized 5,000 shares; none issued and outstanding as of September 30, 2019 and December 31, 2018 | - | - | ||||||
Common stock, $0.0001 par value, 100,000 shares authorized; 37,649 and 35,830 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively | 4 | 4 | ||||||
Additional paid-in capital | 87,758 | 81,499 | ||||||
Accumulated other comprehensive income (loss) | 74 | (2 | ) | |||||
Accumulated deficit | (83,497 | ) | (74,054 | ) | ||||
AgeX Therapeutics, Inc. stockholders’ equity | 4,339 | 7,447 | ||||||
Noncontrolling interest | 604 | 784 | ||||||
Total stockholders’ equity | 4,943 | 8,231 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 8,183 | $ | 10,671 | ||||
AGEX THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS, EXCEPT PER SHARE DATA) (UNAUDITED) | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2019 | 2018 | 2019 | 2018 | |||||||||||||
REVENUES: | ||||||||||||||||
Subscription and advertising revenues | $ | 342 | $ | 373 | $ | 992 | $ | 945 | ||||||||
Grant revenues | 41 | - | 103 | - | ||||||||||||
Other revenues | 28 | 7 | 84 | 138 | ||||||||||||
Total revenues | 411 | 380 | 1,179 | 1,083 | ||||||||||||
Cost of sales | (49 | ) | 4 | (165 | ) | (184 | ) | |||||||||
- | ||||||||||||||||
Gross profit | 362 | 384 | 1,014 | 899 | ||||||||||||
OPERATING EXPENSES: | ||||||||||||||||
Research and development | 1,447 | 1,332 | 4,435 | 4,307 | ||||||||||||
Acquired in-process research and development | - | - | - | 800 | ||||||||||||
General and administrative | 2,194 | 1,254 | 6,422 | 3,679 | ||||||||||||
Total operating expenses | 3,641 | 2,586 | 10,857 | 8,786 | ||||||||||||
Loss from operations | (3,279 | ) | (2,202 | ) | (9,843 | ) | (7,887 | ) | ||||||||
OTHER INCOME/(EXPENSES): | ||||||||||||||||
Interest income, net | 8 | 39 | 53 | 84 | ||||||||||||
Gain on sale of equity method investment in Ascendance | - | - | - | 3,215 | ||||||||||||
Other income/(expense), net | 48 | (22 | ) | 277 | 131 | |||||||||||
Total other income, net | 56 | 17 | 330 | 3,430 | ||||||||||||
NET LOSS BEFORE INCOME TAXES | (3,223 | ) | (2,185 | ) | (9,513 | ) | (4,457 | ) | ||||||||
Income tax provision | (54 | ) | - | (130 | ) | - | ||||||||||
NET LOSS | (3,277 | ) | (2,185 | ) | (9,643 | ) | (4,457 | ) | ||||||||
Net loss attributable to noncontrolling interest | 56 | 34 | 200 | 141 | ||||||||||||
NET LOSS ATTRIBUTABLE TO AGEX | $ | (3,221 | ) | $ | (2,151 | ) | $ | (9,443 | ) | $ | (4,316 | ) | ||||
NET LOSS PER COMMON SHARE: BASIC AND DILUTED | $ | (0.09 | ) | $ | (0.06 | ) | $ | (0.25 | ) | $ | (0.12 | ) | ||||
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED | 37,640 | 35,790 | 37,143 | 34,606 | ||||||||||||
AGEX THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS) (UNAUDITED) | ||||||||
Nine Months Ended September 30, | ||||||||
2019 | 2018 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net loss attributable to AgeX | $ | (9,443 | ) | $ | (4,316 | ) | ||
Net loss attributable to noncontrolling interest | (200 | ) | (141 | ) | ||||
Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities: | ||||||||
Gain on sale of equity method investment in Ascendance | (354 | ) | (3,215 | ) | ||||
Acquired in-process research and development | - | 800 | ||||||
Depreciation expense | 38 | 48 | ||||||
Amortization of intangible assets | 419 | 337 | ||||||
Amortization of right-of-use asset | 200 | - | ||||||
Amortization of debt issuance cost | 17 | - | ||||||
Stock-based compensation | 1,487 | 488 | ||||||
Stock-based compensation allocated from Lineage | - | 184 | ||||||
Subsidiary stock-based compensation | - | 4 | ||||||
Foreign currency remeasurement gain (loss) and other | 85 | (47 | ) | |||||
Changes in operating assets and liabilities: | ||||||||
Accounts and grants receivable, net | (103 | ) | (84 | ) | ||||
Prepaid expenses and other current assets | 331 | (100 | ) | |||||
Accounts payable and accrued liabilities | 319 | 241 | ||||||
Related party payables | 187 | (112 | ) | |||||
Insurance premium liability | (600 | ) | - | |||||
Deferred revenues and other current liabilities | (132 | ) | (36 | ) | ||||
Net cash used in operating activities | (7,749 | ) | (5,949 | ) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Proceeds from the sale of equity method investment in Ascendance | 354 | 3,215 | ||||||
Purchase of in-process research and development | - | (1,872 | ) | |||||
Security deposit paid | (74 | ) | 2 | |||||
Purchase of equipment and other | (346 | ) | (21 | ) | ||||
Net cash (used in) provided by investing activities | (66 | ) | 1,324 | |||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Proceeds from issuance of common shares | - | 5,000 | ||||||
Proceeds from sale of warrants | - | 1,000 | ||||||
Proceeds from exercise of warrants | 4,500 | - | ||||||
Draw down on loan facility from Juvenescence | 500 | - | ||||||
Repayment of financing lease liability | (22 | ) | - | |||||
Net cash provided by financing activities | 4,978 | 6,000 | ||||||
Effect of exchange rate changes on cash and cash equivalents | (2 | ) | 6 | |||||
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (2,839 | ) | 1,381 | |||||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||||||||
At beginning of the period | 6,707 | 7,375 | ||||||
At end of the period | $ | 3,868 | $ | 8,756 | ||||
Non-GAAP Financial Measures
This press release includes operating expenses prepared in accordance with accounting principles generally accepted in the United States (GAAP) and, includes operating expenses, by entity below, prepared in accordance with GAAP. This press release also includes certain historical non-GAAP operating expenses and non-GAAP operating expenses, by entity below. In particular, AgeX Therapeutics, Inc. (“AgeX”) has provided both (a) non-GAAP total operating expenses, adjusted to exclude noncash stock-based compensation expense, depreciation and amortization expense, and acquired in-process research and development expense, a nonrecurring item, and (b) non-GAAP operating expenses, by entity, to exclude those same charges by the respective entities for consistency. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable financial measures prepared in accordance with GAAP. However, AgeX believes the presentation of non-GAAP total operating expenses and non-GAAP operating expenses, by entity, when viewed in conjunction with our GAAP total operating expenses, and GAAP operating expenses by entity, respectively, is helpful in understanding AgeX’s ongoing operating expenses and its programs and those of certain subsidiaries.
AGEX THERAPEUTICS, INC. AND SUBSIDIARIES | |||||||||||||
Reconciliation of Non-GAAP Financial Measure | |||||||||||||
Adjusted Operating Expenses | |||||||||||||
Amounts In Thousands and
| Amounts In Thousands and
| ||||||||||||
For the Three Months Ended
| For the Nine Months Ended
| ||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||
GAAP Operating Expenses - as reported | $ | 3,641 | $ | 2,586 | $ | 10,857 | $ | 8,786 | |||||
Stock-based compensation expense (1) | (491) | (210) | (1,487) | (676) | |||||||||
Amortization of right-of-use assets (1) | (101) | - | (200) | - | |||||||||
Depreciation and amortization expense (1) | (156) | (146) | (457) | (385) | |||||||||
Acquired in-process research and development expense (2) | - | - | - | (800) | |||||||||
Non-GAAP Operating Expenses, as adjusted | $ | 2,893 | $ | 2,230 | $ | 8,713 | $ | 6,925 | |||||
GAAP Operating Expenses - by entity | |||||||||||||
AgeX and subsidiaries other than LifeMap Sciences (3) | $ | 3,114 | $ | 2,027 | $ | 9,150 | $ | 7,050 | |||||
LifeMap Sciences, Inc. and subsidiary (4) | 527 | 559 | 1,707 | 1,736 | |||||||||
GAAP Operating Expenses - by entity | $ | 3,641 | $ | 2,586 | $ | 10,857 | $ | 8,786 | |||||
Non-GAAP Operating Expenses - as adjusted, by entity | |||||||||||||
AgeX and subsidiaries other than LifeMap Sciences | $ | 2,482 | $ | 1,782 | $ | 7,352 | $ | 5,524 | |||||
LifeMap Sciences, Inc. and subsidiary | 411 | 448 | 1,361 | 1,401 | |||||||||
Non-GAAP Operating Expenses - as adjusted, by entity | $ | 2,893 | $ | 2,230 | $ | 8,713 | $ | 6,925 | |||||
(1) | Noncash charges | |
(2) | AgeX acquired certain in-process research and development expense in March 2018, considered to be a nonrecurring item. | |
(3) | AgeX Therapeutics, Inc. includes ReCyte Therapeutics, Inc., a majority-owned and consolidated subsidiary. | |
(4) | LifeMap Sciences Inc. includes LifeMap Sciences Ltd., both consolidated subsidiaries of AgeX Therapeutics, Inc. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20191114005826/en/
Contacts:
Bill Douglass
Gotham Communications, LLC
bill@gothamcomm.com
(646) 504-0890
